161 related articles for article (PubMed ID: 37324117)
1. Association between micronutrients, oxidative stress biomarkers and angiogenic growth mediators in early and late-onset preeclamptic Ghanaian women.
Anto EO; Ofori Boadu WI; Addai-Mensah O; Wiafe YA; Owiredu WK; Obirikorang C; Annani-Akollor ME; Adua E; Appiah M; Opoku S; Acheampong E; Asamoah EA; Owiredu EW; Odame Anto A; Tawiah A; Ankobea F; Afrifa Yamoah E; Coall DA
SAGE Open Med; 2023; 11():20503121231175759. PubMed ID: 37324117
[TBL] [Abstract][Full Text] [Related]
2. Placental lesions and differential expression of pro-and anti-angiogenic growth mediators and oxidative DNA damage marker in placentae of Ghanaian suboptimal and optimal health status pregnant women who later developed preeclampsia.
Anto EO; Coall DA; Asiamah EA; Afriyie OO; Addai-Mensah O; Wiafe YA; Owiredu W; Obirikorang C; Annani-Akollor ME; Titiloye NA; Adua E; Acheampong E; Adu EA; Opoku S; Anto AO; Tawiah A; Wang Y; Wang W
PLoS One; 2022; 17(3):e0265717. PubMed ID: 35312727
[TBL] [Abstract][Full Text] [Related]
3. Suboptimal health pregnant women are associated with increased oxidative stress and unbalanced pro- and antiangiogenic growth mediators: a cross-sectional study in a Ghanaian population.
Anto EO; Roberts P; Coall DA; Adua E; Turpin CA; Tawiah A; Wang Y; Wang W
Free Radic Res; 2020 Jan; 54(1):27-42. PubMed ID: 31814473
[TBL] [Abstract][Full Text] [Related]
4. An analysis on the roles of angiogenesis-related factors including serum vitamin D, soluble endoglin (sEng), soluble fms-like tyrosine kinase 1 (sFlt1), and vascular endothelial growth factor (VEGF) in the diagnosis and severity of late-onset preeclampsia.
Cim N; Kurdoglu M; Ege S; Yoruk I; Yaman G; Yildizhan R
J Matern Fetal Neonatal Med; 2017 Jul; 30(13):1602-1607. PubMed ID: 27658884
[TBL] [Abstract][Full Text] [Related]
5. First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia.
Nzelu D; Biris D; Karampitsakos T; Nicolaides KK; Kametas NA
Am J Obstet Gynecol; 2020 Apr; 222(4):374.e1-374.e9. PubMed ID: 31705883
[TBL] [Abstract][Full Text] [Related]
6. Angiogenic and vasoactive proteins in the maternal-fetal interface in healthy pregnancies and preeclampsia.
Westerberg AC; Degnes ML; Andresen IJ; Roland MCP; Michelsen TM
Am J Obstet Gynecol; 2024 Mar; ():. PubMed ID: 38494070
[TBL] [Abstract][Full Text] [Related]
7. Novel circulating placental markers prokineticin-1, soluble fms-like tyrosine kinase-1, soluble endoglin and placental growth factor and association with late miscarriage.
Jayasena CN; Abbara A; Comninos AN; Narayanaswamy S; Gonzalez Maffe J; Izzi-Engbeaya C; Oldham J; Lee TT; Sarang Z; Malik Z; Dhanjal MK; Williamson C; Regan L; Bloom SR; Dhillo WS
Hum Reprod; 2016 Dec; 31(12):2681-2688. PubMed ID: 27664209
[TBL] [Abstract][Full Text] [Related]
8. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
Holme AM; Roland MC; Henriksen T; Michelsen TM
Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
[TBL] [Abstract][Full Text] [Related]
9. The additive role of angiogenic markers for women with confirmed preeclampsia.
Suresh S; Patel E; Mueller A; Morgan J; Lewandowski WL; Verlohren S; von Dadelszen P; Magee LA; Rana S
Am J Obstet Gynecol; 2023 May; 228(5):573.e1-573.e11. PubMed ID: 36356699
[TBL] [Abstract][Full Text] [Related]
10. High early pregnancy body mass index is associated with alterations in first- and second-trimester angiogenic biomarkers.
Beck C; Allshouse A; Silver RM; Grobman WA; Simhan H; Haas D; Reddy UM; Blue NR
Am J Obstet Gynecol MFM; 2022 May; 4(3):100614. PubMed ID: 35283347
[TBL] [Abstract][Full Text] [Related]
11. Early gestational profiling of oxidative stress and angiogenic growth mediators as predictive, preventive and personalised (3P) medical approach to identify suboptimal health pregnant mothers likely to develop preeclampsia.
Anto EO; Coall DA; Addai-Mensah O; Wiafe YA; Owiredu WKBA; Obirikorang C; Annani-Akollor ME; Adua E; Tawiah A; Acheampong E; Asamoah EA; Wang X; Opoku S; Boakye DK; Hou H; Wang Y; Wang W;
EPMA J; 2021 Dec; 12(4):517-534. PubMed ID: 34956424
[TBL] [Abstract][Full Text] [Related]
12. Sequential plasma angiogenic factors levels in women with suspected preeclampsia.
Baltajian K; Bajracharya S; Salahuddin S; Berg AH; Geahchan C; Wenger JB; Thadhani R; Karumanchi SA; Rana S
Am J Obstet Gynecol; 2016 Jul; 215(1):89.e1-89.e10. PubMed ID: 26827880
[TBL] [Abstract][Full Text] [Related]
13. Adverse pregnancy outcomes and imbalance in angiogenic growth mediators and oxidative stress biomarkers is associated with advanced maternal age births: A prospective cohort study in Ghana.
Odame Anto E; Owiredu WKBA; Sakyi SA; Turpin CA; Ephraim RKD; Fondjo LA; Obirikorang C; Adua E; Acheampong E
PLoS One; 2018; 13(7):e0200581. PubMed ID: 30016351
[TBL] [Abstract][Full Text] [Related]
14. Differences and similarities in endothelial and angiogenic profiles of preeclampsia and COVID-19 in pregnancy.
Palomo M; Youssef L; Ramos A; Torramade-Moix S; Moreno-Castaño AB; Martinez-Sanchez J; Bonastre L; Pino M; Gomez-Ramirez P; Martin L; Garcia Mateos E; Sanchez P; Fernandez S; Crovetto F; Escolar G; Carreras E; Castro P; Gratacos E; Crispi F; Diaz-Ricart M
Am J Obstet Gynecol; 2022 Aug; 227(2):277.e1-277.e16. PubMed ID: 35351411
[TBL] [Abstract][Full Text] [Related]
15. Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension.
Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
Am J Obstet Gynecol; 2021 Sep; 225(3):305.e1-305.e14. PubMed ID: 33812812
[TBL] [Abstract][Full Text] [Related]
16. Prediction of imminent preeclampsia at 35-37 weeks gestation.
Ciobanu A; Wright A; Panaitescu A; Syngelaki A; Wright D; Nicolaides KH
Am J Obstet Gynecol; 2019 Jun; 220(6):584.e1-584.e11. PubMed ID: 30738886
[TBL] [Abstract][Full Text] [Related]
17. Angiogenic factors and uterine Doppler velocimetry in early- and late-onset preeclampsia.
Tobinaga CM; Torloni MR; Gueuvoghlanian-Silva BY; Pendeloski KP; Akita PA; Sass N; Daher S
Acta Obstet Gynecol Scand; 2014 May; 93(5):469-76. PubMed ID: 24580069
[TBL] [Abstract][Full Text] [Related]
18. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Tuohey L; Parry LJ; Senadheera S; Illanes SE; Kaitu'u-Lino TJ; Tong S
Am J Obstet Gynecol; 2016 Mar; 214(3):356.e1-356.e15. PubMed ID: 26721779
[TBL] [Abstract][Full Text] [Related]
19. A longitudinal analysis of angiotensin II type 1 receptor antibody and angiogenic markers in pregnancy.
Aggarwal S; Sunderland N; Thornton C; Xu B; Hennessy A; Makris A
Am J Obstet Gynecol; 2017 Feb; 216(2):170.e1-170.e8. PubMed ID: 27793555
[TBL] [Abstract][Full Text] [Related]
20. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.
Govender N; Naicker T; Rajakumar A; Moodley J
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):100-5. PubMed ID: 23806447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
